NEW YORK (GenomeWeb News) – Complete Genomics reported after the close of the market Monday that its first-quarter revenues declined 43 percent year over year, falling short of Wall Street's consensus estimate on the top line.

The Mountain View, Calif.-based whole human genome services firm had total revenues of $3.9 million for the three months ended March 31, compared to $6.8 million for the first quarter of 2011. Analysts, on average, expected sales of $4.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.